ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER.
Radiotherapy (RT)
abiraterone
androgen deprivation therapy (ADT)
androgen receptor
androgen receptor targeted agents (ARTAs)
enzalutamide
prostate cancer
Journal
Acta clinica Croatica
ISSN: 1333-9451
Titre abrégé: Acta Clin Croat
Pays: Croatia
ID NLM: 9425483
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
22
3
2023
Statut:
ppublish
Résumé
Anti-androgen therapy continues to be a basic pilar of treatment for both localized and metastatic prostate cancer. The advent of new generation of androgen receptor targeted agents (ARTA) transformed the care of patients with advanced disease. After such a success, the steps were taken to incorporate a new generation of ARTAs into the treatment landscape of localized prostate cancer. High-risk prostate cancer represents the most aggressive form of localized disease with significant metastatic potential and poor outcome. Here, the impact of novel therapies will likely be profound and transforming. This clinical space has already been a showcase for multidisciplinary treatment where the combination of local therapies with systemic treatment gradually improved patient outcomes and the chances of cure. The most recent step in redefining the treatment of localized disease is the adoption of novel ARTAs moving forward the multidisciplinary platform. In this narrative review, we discuss current clinical evidence supporting the use of novel ARTAs in patients with localized high-risk prostate cancer and cover recent developments in biomarker-driven strategies for treatment individualization in this clinical context.
Identifiants
pubmed: 36938555
doi: 10.20471/acc.2022.61.s3.7
pii: acc-61_supp3-51
pmc: PMC10022413
doi:
Substances chimiques
Receptors, Androgen
0
Androgen Antagonists
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-56Références
Eur Urol. 2021 Oct;80(4):522-523
pubmed: 34274134
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38
pubmed: 30131604
Nat Rev Urol. 2013 Feb;10(2):90-8
pubmed: 23247694
JAMA. 2005 May 4;293(17):2095-101
pubmed: 15870412
J Urol. 2007 Jan;177(1):113-7
pubmed: 17162017
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Lancet Oncol. 2015 Mar;16(3):320-7
pubmed: 25702876
Eur Urol. 2012 Jan;61(1):11-25
pubmed: 21871711
N Engl J Med. 2022 Mar 24;386(12):1132-1142
pubmed: 35179323
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):364-372
pubmed: 29263420
Am Soc Clin Oncol Educ Book. 2020 May;40:1-12
pubmed: 32412803
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Lancet. 2002 Jul 13;360(9327):103-6
pubmed: 12126818
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Clin Oncol. 2017 Jun 20;35(18):1991-1998
pubmed: 28358655
J Clin Oncol. 2014 Nov 20;32(33):3705-15
pubmed: 25311217
Sci Rep. 2019 May 28;9(1):7956
pubmed: 31138829
J Clin Oncol. 2010 Mar 1;28(7):1117-23
pubmed: 20124165
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302
pubmed: 26209502
Eur Urol. 2017 Nov;72(5):845-852
pubmed: 28528811
N Engl J Med. 2017 Feb 2;376(5):417-428
pubmed: 28146658
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
Eur Urol. 2017 Feb;71(2):151-154
pubmed: 27477525
JAMA Oncol. 2021 Apr 1;7(4):544-552
pubmed: 33570548
JAMA Oncol. 2017 Dec 1;3(12):1663-1672
pubmed: 28494073
J Clin Oncol. 2008 Feb 1;26(4):585-91
pubmed: 18172188
Eur Urol. 2018 Oct;74(4):432-441
pubmed: 29980331
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90
pubmed: 15817329
JAMA Oncol. 2016 Mar;2(3):348-57
pubmed: 26606329